<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe manifestations of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), and thrombotic thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="1" ids="18284">TTP</z:chebi>) are characterized by multiorgan <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe reduction of ADAMTS13 activity and the development of systemic <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> 8 children initially diagnosed with acquired noncongenital <z:chebi fb="1" ids="18284">TTP</z:chebi> during an 8.5-year period </plain></SENT>
<SENT sid="2" pm="."><plain>Median age at diagnosis was 12.0 years (range, 2.6-17.3 years) </plain></SENT>
<SENT sid="3" pm="."><plain>ADAMTS13 activity was absent (&lt;5%) in 6 patients; 3 patients had a detected inhibitor </plain></SENT>
<SENT sid="4" pm="."><plain>SLE was diagnosed concurrently in 3 patients, and 4 patients were diagnosed within 5 years </plain></SENT>
<SENT sid="5" pm="."><plain>Six of the children diagnosed with SLE had absent ADAMTS13 activity at diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>In 6 patients with SLE, immune-mediated <z:hpo ids='HP_0000123'>nephritis</z:hpo> developed by 46 months </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> surviving patients with SLE developed <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, including some with a <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with SLE did not have <z:chebi fb="1" ids="18284">TTP</z:chebi> recurrences once daily immunosuppressive regimens were started </plain></SENT>
<SENT sid="9" pm="."><plain>An evaluation for SLE/APS is warranted in children and adolescents with reduced ADAMTS13 activity and <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> </plain></SENT>
</text></document>